## CLAIMS

1. A benzothiazin-3-one compound represented by the formula (1):

$$RO_2C$$
 $(CH_2)_n$ 
 $RO_2C$ 
 $(1)$ 

wherein n is 3 or 4; R is an ethyl group or a hydrogen atom; and  $R^1$  is a halogen atom, an alkoxy group, a haloalkyl group or a haloalkoxy group, or a pharmaceutically acceptable salt thereof.

- 2. A benzothiazin-3-one compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (1),  $R^1$  is a fluorine atom, a chlorine atom, a methoxy group, a trifluoromethyl group or a trifluoromethoxy group.
- 3. A benzothiazin-3-one compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein in the formula (1), the configuration relating to the carbon atom at the 2-position is an S-configuration.
- 4. A benzothiazin-3-one compound or a pharma-ceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R is an ethyl group.
- A benzothiazin-3-one compound or a pharma-ceutically acceptable salt thereof according to any one of claims 1 to 3, wherein R is a hydrogen atom.

- A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by the formula (1) is (-)-ethyl 4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate.
- A compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by the formula (1) is (-)-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-carboxylic acid.
- 8. A pharmaceutical composition comprising a benzothiazin-3-one compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient.
- 9. A matrix metallo-proteinase inhibitor comprising a benzothiazin-3-one compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient.
- 10. A pharmaceutical composition for the treatment or prophylaxis of chondrodegenerative diseases or inflammatory diseases comprising a benzothiazin-3-one compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient.
- 11. A compound represented by the formula (2):

$$HO$$
  $(CH_2)_n$   $R^1$   $(2)$ 

wherein n is 3 or 4;  $R^1$  is a halogen atom, an alkoxy group, a haloalkyl group or a haloalkoxy group; and  $R^2$  is an alkyl group of 2 or 3 carbon atoms, a 4-nitrobenzyl group or a 2,2,2-trichloroethyl group.

- 12. A compound according to claim 11, wherein the alkyl group of 2 or 3 carbon atoms is an ethyl group.
- 13. A compound according to claims 11 or 12, which has an S-configuration.
- 14. A compound according to claims 11 or 12, which has an R-configuration.
- 15. A compound represented by the formula (3):

$$Br (CH2)n R1$$
(3)

wherein n is 3 or 4; R<sup>1</sup> is a halogen atom, an alkoxy group, a haloalkyl group or a haloalkoxy group; and R<sup>10</sup> is a hydrogen atom, an alkyl group of 1 to 6 carbon atoms, a 4-nitrobenzyl group or a 2,2,2-trichloroethyl group.

- 16. A compound according to claim 15, wherein the alkyl group of 1 to 6 carbon atoms is a methyl group or an ethyl group.
- 17. A compound according to claim 15 or 16, which

has an S-configuration.

18. A compound according to claim 15 or 16, which has an R-configuration.